Masa ósea y fracturas en enfermedades reumatológicas autoinmunes
Resumen
El remodelado óseo es un proceso continuo que ocurre a través de la vida; en condiciones fisiológicas normales, los osteoblastos están involucrados en la formación del osteoide el cual es mineralizado y reemplaza el hueso en los sitios donde el osteoclasto produjo resorción ósea para mantener la integridad esquelética.Citas
I. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000; 39:1383-1389.
II. Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux C. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int. 2012;23:581-587.
III. Canalis E, Giustina A, Bilezikian JP. Mechanisms of Anabolic Therapies for Osteoporosis. N Engl J Med. 2007;357(9):905-916.
IV. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007;40(2):251-264.
V. Gillespie MT. Impact of cytokines and T lymphocytes upon osteoclast differentiation and function. Arthritis Res Ther. 2007;9(2):103.
VI. Sims NA, Jenkins BJ, Nakamura A, et al. Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res. 2005;20(7):1093-1102.
VII. Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol. 2010;54(2):123-132.
VIII. Krishnamurthy A, Joshua V, Haj Hensvold A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016;75:721-729.
IX. Fassio A, Idolazzi L, Jaber MA, Dartizio C, Viapiana O, Rossini M, Gatti D. The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo. 2016; 68(2):65-71.
X. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43(3):522-530.
XI. Makhdoom A, Rahopoto MQ, Awan S, et al. Bone mineral density level by dual energy X-ray absorptiometry in rheumatoid arthritis. J Pak Med Assoc. 2017;67(1):15-19.
XII. Vis M, Haavardsholm EA, Bøyesen P, et al. High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int. 2011;22:2413-2419.
XIII. Okano T, Inui K, Tada M, et al. High frequency of vertebral fracture and low bone quality in patients with rheumatoid arthritis-Results from TOMORROW study. Mod Rheumatol. 2016;2:1-7.
XIV. Saad CG, Ribeiro AC, Moraes JC, et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther. 2012;14(5):R216.
XV. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60:3257-3262.
XVI. François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006;65:713-720.
XVII. Taylan A, Sari I, Akinci B, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2012:2;13:191.
XVIII. Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford). 2006;45(10):1197-1200.
XIX. Klingberg E, Nurkkala M, Carlsten H, Forsblad-d’Elia H. Biomarkers of bone metabolism In ankylosing spondylitis in relation to osteoproliferation and osteoporosis. Rheumatol. 2014;41(7):1349-56.
XX. El Maghraoui A, Ebo’o FB, Sadni S, Majjad A, Hamza T, Mounach A. Is there a relation between pre-sarcopenia, sarcopenia, cachexia and osteoporosis in patients with ankylosingspondylitis? BMC Musculoskelet Disord. 2016; 11;17:268.
XXI. Leone A, Marino M, Dell’Atti C, Zecchi V, Magarelli N, Colosimo C. Spinal fractures in patients with ankylosing spondylitis. Rheumatol Int. 2016;36(10):1335-46.
XXII. Mitra D, Elvins DM, Speden DJ, Collins AJ. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineraldensity. Rheumatology (Oxford). 2000;39(1):85-9.
XXIII. Feldtkeller E, Vosse D, Geusens P, van der Linden S. Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis. Rheumatol Int. 2006;26(3):234-9.
XXIV. Maas F, Spoorenberg A, van der Slik BP, et al. Clinical risk factors for the presence and development of vertebral fractures in patients with ankylosingspondylitis. Arthritis Care Res (Hoboken). 2016 . doi: 10.1002/acr.22980.
XXV. Maas F, Spoorenberg A, Brouwer E, et al. Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF-^ blocking therapy. Clin Exp Rheumatol. 2016;34(2):191-199.
XXVI. Van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE. Etanercept increases bone mineral density in ankylosing spondylitis, but does not prevent vertebral fractures: results of a prospective observational cohort study. J Rheumatol. 2016;43(4):758-764.
XXVII. Chandran S, Aldei A, Johnson SR, Cheung AM, Salonen D, Gladman DD. Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. Semin Arthritis Rheum. 2016;46(2):174-82.
XXVIII. Del Puente A, Esposito A, Costa L, et al. Fragility fractures in patients with psoriatic arthritis. J Rheumatol Suppl. 2015;93:36-9.
XXIX. Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther. 2011;13:R16.
XXX. Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specific association? J Invest Dermatol. 2009;129:1643-1649.
XXXI. Gilboe IM, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis. 2000;59(2):110-115.
XXXII. Sheane BJ, Gladman DD, Su J, Urowitz MB. Disease outcomes in corticosteroid-naïve patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017; 69(2):252-256.
XXXIII. Cramarossa G, Urowitz MB, Su J, Gladman D, Touma Z. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus. Lupus. 2016. pii: 0961203316664597.
XXXIV. Both T, Zillikens MC, Hoorn EJ, et al. Bone Mineral Density in Sjögren Syndrome Patients with and Without Distal Renal Tubular Acidosis. Calcif Tissue Int. 2016;98(6):573-579.
XXXV. Calvo L, Pistone G, Arnone S, et al. Polymyalgia rheumatica and vertebral fractures: a 1-year pilot controlled study. Rheumatol Int. 2010;30(9):1245-1247.
XXXVI. Zhu TY, Griffith JF, Qin L, et al. Alterations of bone density, microstructure, and strength of the distal radius in male patients with rheumatoid arthritis: a case-control study with HR-pQCT. J Bone Miner Res. 2014;29(9):2118-2129.
XXXVII. Nigil Haroon N, Szabo E, Raboud JM, et al. Alterations of bone mineral density, bone microarchitecture and strength in patients with ankylosingspondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis. Arthritis Res Ther. 2015;17:377.
XXXVIII. Zhu TY, Griffith JF, Qin L, et al. Density, structure, and strength of the distal radius in patients with psoriatic arthritis: the role of inflammation and cardiovascular risk factors. Osteoporos Int. 2015;26(1):261-272.
XXXIX. Dolan AL, Moniz C, Abraha H, Pitt P. Does active treatment of rheumatoid arthritis limit disease-associated bone loss? Rheumatology (Oxford). 2002;41(9):1047-51.
XL. Zerbini CA, Clark P, Mendez-Sanchez L, et al. Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int. 2017;28(2):429-446.
XLI. Orsolini G, Adami G, Adami S, et al. Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis. Calcif Tissue Int. 2016;98(6):580-5.
XLII. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68(3):373-6.
XLIII. Chopin F, Garnero P, le Henanff A, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(3):353-7.
XLIV. Dischereit G, Tarner IH, Müller-Ladner U, Lange U. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol. 2013;32(3):377-81.
XLV. Allali F, Breban M, Porcher R, et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor ^.Ann Rheum Dis. 2003; 62(4): 347-349.
XLVI. Haroon NN, Sriganthan J, Al Ghanim N, et al. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):155-161.
XLVII. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:420-7.
XLVIII. Briot K, Rouanet S, Schaeverbeke T, et al. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine. 2015;82(2):109-115.
XLIX. Karsdal MA, Schett G, Emery P, et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum. 2012;42(2):131-139.
L. Mendoza Pinto C, García Carrasco M, Etchegaray Morales I, et al. Bone mineral density in systemic lupus erythematosus women one year after rituximab therapy. Lupus. 2013;22(11):1128-1134.
LI. Hein G, Eidner T, Oelzner P, et al. Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol Int. 2011;31(2):269-272.
LII. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224-3229.
LIII. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-268.
LIV. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-787.
LV. Brance ML, Plantalech L. Osteoporosis inducida por glucocorticoides: análisis de las guías internacionales de prevención y tratamiento. Actual Osteol. 2013;9(1):14-27.
LVI. Messina OD, Somma LF, Tamborenea MI, Castelli G, Riopedre AM, Lancioni G, Larroude MS. Guías para el diagnóstico, la prevención y el tratamiento de la osteoporosis inducida por corticoides en el adulto. Actual Osteol. 2016; 12(2):107-125.
LVII. Orbach H, Zandman-Goddard G, Amital H, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 2007; 1109:385-340.
LVIII. Vacca A, Cormier C, Piras M, Mathieu A, Kahan A, Allanore Y. Vitamin D deficiency and insufficiency in two independent cohorts of patients with systemic sclerosis. J Rheumatol. 2009;36:1924-1929.
LIX. Hajas A, Sandor J, Csathy L, et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev. 2011;10:317-324.
LX. Mandal M, Tripathy R, Panda AK, et al. Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis Res Ther. 2014;16(1):R49.
LXI. . Brance ML, Brun LR, Lioi S, Sánchez A, Abdala M, Oliveri B. Vitamin D levels and bone mass in rheumatoid arthritis. Rheumatol Int. 2015;35(3):499-505.
LXII. Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am. 2010;39:255-269.
LXIII. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med. 2010; 88:441-450.
LXIV. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007;179:1634-1647.
LXV. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D:modulator of the immune system. Curr Opin Pharmacol. 2010;10:482-496.
LXVI. Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat Immunol. 2007;8:285-293.
LXVII. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929-939.
LXVIII. Toloza SM, Cole DE, Gladman DD, Ibañez D, Urowitz MB. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010;19:13-19.
LXIX. Amital H, Szekanecz Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010;69:1155-1157.
LXX. Cutolo M, Otsa K, Paolino S, Yprus M, Veldi T, Seriolo B. Vitamin D involvement in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2009; 68:446-447.
LXXI. Kim HA, Sung JM, Jeon JY, Yoon JM, Suh CH. Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol Int. 2011;31(9):1189-1194.
LXXII. Brance ML, Brun LR, Larroude MS, et al. Evaluation of 25-hydroxyvitamin D levels in rheumatologic diseases. 2016 ACR-ARHP Annual Meeting [Abstract 341].
Derechos de autor 2017 Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
